Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Total Liabilities (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Total Liabilities for 8 consecutive years, with $56.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Liabilities fell 15.62% to $56.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $56.8 million, a 15.62% decrease, with the full-year FY2025 number at $50.8 million, changed N/A from a year prior.
  • Total Liabilities was $56.8 million for Q4 2025 at Outlook Therapeutics, up from $50.8 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $67.3 million in Q4 2024 to a low of $50.8 million in Q3 2025.